ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (AMEX:ISV) announced today that it has filed a New Drug Submission (NDS) with Health Canada seeking regulatory approval to market the topical ocular antibiotic AzaSite® (azithromycin ophthalmic solution) 1% for the treatment of bacterial conjunctivitis (pink eye) in Canada.
